These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 27413840)

  • 1. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S; Weinstock-Guttman B
    Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PML: underdiagnosed in MS patients on natalizumab.
    Steiner I
    Lancet Neurol; 2010 Jun; 9(6):564; author reply 564-5. PubMed ID: 20494319
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab therapy for multiple sclerosis.
    Derfuss T; Kuhle J; Lindberg R; Kappos L
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab in Multiple Sclerosis: Long-Term Management.
    Clerico M; Artusi CA; Liberto AD; Rolla S; Bardina V; Barbero P; Mercanti SF; Durelli L
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
    Igra MS; Paling D; Wattjes MP; Connolly DJA; Hoggard N
    Br J Radiol; 2017 Jun; 90(1074):20160721. PubMed ID: 28362522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
    Fernández O; García-Merino JA; Arroyo R; Álvarez-Cermeño JC; Izquierdo G; Saiz A; Olascoaga J; Rodríguez-Antigüedad A; Prieto JM; Oreja-Guevara C; Hernández MA; Moral E; Meca J; Montalbán X
    Neurologia; 2015 Jun; 30(5):302-14. PubMed ID: 24360652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
    Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
    Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
    McGuigan C; Craner M; Guadagno J; Kapoor R; Mazibrada G; Molyneux P; Nicholas R; Palace J; Pearson OR; Rog D; Young CA
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):117-25. PubMed ID: 26492930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL
    Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
    BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
    Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.